Cytokinetics, Incorporated
CYTK
शेयरों में रैंक
#2268
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
शेयर मूल्य
$63.18
मार्केट कैप
$8.78B
बदलाव (1 दिन)
-1.21%
बदलाव (1 वर्ष)
9.34%
देश
US
व्यापार Cytokinetics, Incorporated (CYTK)
श्रेणी
Healthcare
Cytokinetics, Incorporated (CYTK) के लिए राजस्व
Jun 2026 में राजस्व TTM: $70.96M
Cytokinetics, Incorporated की नवीनतम वित्तीय रिपोर्टों के अनुसार, कंपनी की वर्तमान राजस्व (TTM) $70.96M है। 2023 में, कंपनी ने $7.53M का राजस्व अर्जित किया जो 2022 के $94.59M के राजस्व से की तुलना में कमी है। राजस्व वह कुल आय है जो कंपनी अपने उत्पादों या सेवाओं की बिक्री से उत्पन्न करती है। लाभ की तुलना में इसमें कोई खर्च घटाया नहीं जाता।
Cytokinetics, Incorporated के लिए 2000 से 2026 तक की राजस्व इतिहास
प्रत्येक वर्ष के अंत में राजस्व
| वर्ष | राजस्व | परिवर्तन |
|---|---|---|
| 2026 (TTM) | $70.96M | 284.11% |
| 2024 | $18.47M | 145.34% |
| 2023 | $7.53M | -92.04% |
| 2022 | $94.59M | 34.30% |
| 2021 | $70.43M | 26.15% |
| 2020 | $55.83M | 107.79% |
| 2019 | $26.87M | -14.71% |
| 2018 | $31.50M | 135.64% |
| 2017 | $13.37M | -87.44% |
| 2016 | $106.41M | 271.30% |
| 2015 | $28.66M | -38.95% |
| 2014 | $46.94M | 53.16% |
| 2013 | $30.65M | 305.45% |
| 2012 | $7.56M | 88.98% |
| 2011 | $4.00M | 55.22% |
| 2010 | $2.58M | -96.84% |
| 2009 | $81.54M | 556.51% |
| 2008 | $12.42M | -8.82% |
| 2007 | $13.62M | 335.63% |
| 2006 | $3.13M | -64.91% |
| 2005 | $8.91M | -33.70% |
| 2004 | $13.44M | 27.09% |
| 2003 | $10.58M | -7.19% |
| 2002 | $11.40M | 34.61% |
| 2001 | $8.47M | 0.00% |
| 2000 | 0.00 | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के लिए राजस्व
| कंपनी | राजस्व | राजस्व में अंतर | देश |
|---|---|---|---|
| $12.62B | 17,690.73% |
US
|
|
| $2.23B | 3,039.80% |
US
|
|
| $15.74B | 22,087.61% |
AU
|
|
| $6.02B | 8,385.47% |
NL
|
|
| - | - |
CH
|
